as of 11-13-2026 3:36pm EST
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.
| Founded: | 1961 | Country: | United States |
| Employees: | 30000 | City: | CANONSBURG |
| Market Cap: | 21.0B | IPO Year: | 2019 |
| Target Price: | $21.00 | AVG Volume (30 days): | 9.0M |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | -0.23 | EPS Growth: | -466.04 |
| 52 Week Low/High: | $10.15 - $21.20 | Next Earning Date: | 11-05-2026 |
| Revenue: | $14,299,900,000 | Revenue Growth: | -2.98% |
| Revenue Growth (this year): | 3.53% | Revenue Growth (next year): | 3.69% |
| P/E Ratio: | -90.37 | Index: | |
| Free Cash Flow: | 1.9B | FCF Growth: | +27.13% |
SEC 8-K filings with transcript text
Nov 5, 2026 · 100% conf.
1D
+2.74%
$19.75
Act: +4.14%
5D
+6.21%
$20.41
20D
+1.94%
$19.59
2 exhibit991-3q26earningsrel.htm
Document
Viatris Reports Third-Quarter 2026 Financial Results
•Delivers Total Revenues of $3.75 Billion, U.S. GAAP Net Loss of $325 Million and Adjusted EBITDA of $1.20 Billion
•Receives Regulatory Approval for RYZUMVI® for Presbyopia in the U.S. and WAKIX® in Japan
•Returns Approximately $717 Million of Capital to Shareholders Year to Date, Including Through Share Repurchases
•Advances Innovative Medicines Strategy with Planned Acquisition of Pacira BioSciences, Expected to Close by the End of November
•Raises 2026 Financial Guidance Midpoints for All Metrics [1]
PITTSBURGH – Nov. 5, 2026 – Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced its third-quarter 2026 financial results.
Executive Commentary
“Our third-quarter results reflect strong execution and reinforce our confidence in the growth trajectory of our business,” said Scott A. Smith, CEO, Viatris. “Momentum across key areas of our base business, progress in our pipeline and the benefits of our enterprise-wide strategic review continue to strengthen our company. With the recent U.S. launch of Gwyn Lo, approvals of RYZUMVI in the U.S. and WAKIX in Japan, the potential upcoming approval and launch of fast-acting meloxicam and our recently announced agreement to acquire Pacira BioSciences, we are taking important steps to position Viatris for sustained revenue and earnings growth.”
“We are very pleased with the operational momentum across our higher-margin businesses and continued focus on cost discipline, which led to strong overall third-quarter results,” said Paul Campbell, Interim CFO, Chief Accounting Officer & Corporate Controller, Viatris. “Based on this performance and our confidence in the outlook for the rest of the year, we are once again raising the midpoints of our financial guidance ranges across all key metrics. Also, consistent with our disciplined and balanced capital allocation strategy, we continued returning additional value to shareholders in the quarter and expect the Pacira transaction to have minimal impact on our gross leverage ratio upon expected closing by the end of November.”
[1] Viatris is not providing forward-looking guidance for U.S. GAAP net earnings (loss) or U.S. GAAP diluted EPS (loss) or a quantitative reconciliation of its 2026 adjusted EBITDA or adjusted EPS guidance. U.S. GAAP net cash provided by operating activities for 2026 is estimated to be between $2.025 billion and $2.1 billion, with a midpoint of approximately $2.0625 billion. 2026 financial guidance ranges as provided on November 5, 2026, exclude the impact of any transaction-related and restructuring-related costs (as defined below) and acquired IPR&D for unsigned deals as they cannot be reasonably forecasted. 2026 financial guidance ranges also exclude any contribution from the planned acquisition of Pacira BioSciences. Please see “2026 Financial Guidance” and “Non-GAAP Financial Measures” for additional information.
2
Third-Quarter Results
Three Months Ended
September 30,
(Unaudited; in millions, except %s and per share amounts) 20262025 Reported Change
Operational Change(1) (2)
Total Revenues $3,749.5 $3,759.9 —%—%
Total Net Sales$3,734.7 $3,747.5 —%—%
Developed Markets2,215.9 2,255.6 (2)%(1)%
Emerging Markets529.1 570.4 (7)%(6)%
Greater China702.6 615.2 14%10%
Net Sales by Product Category
Brands$2,461.4 $2,436.8 1%1%
Generics 1,273.3 1,310.7 (3)%(3)%
U.S. GAAP Gross Profit$1,438.0 $1,371.5 5%
U.S. GAAP Gross Margin38.4 %36.5 %
Adjusted Gross Profit (2) $2,176.0 $2,104.4 3%
Adjusted Gross Margin (2) 58.0 %56.0 %
U.S. GAAP Net Loss$(325.3)$(128.2)NM
U.S. GAAP Loss Per Share$(0.28)$(0.11)NM
Adjusted Net Earnings (2) $821.4 $784.3 5%
Adjusted EPS (2) $0.71 $0.67 6%3%
$937.5 $800.2 17%
Adjusted EBITDA (2) $1,195.7 $1,154.6 4%1%
U.S. GAAP Net Cash Provided by Operating Activities $899.4 $744.9 21%
Capital Expenditures 85.7 86.8 (1)%
Free Cash Flow (2)(3) $813.7 $658.1 24%
(1) See “Certain Key Terms and Presentation Matters” in this release for more information.
(2) Non-GAAP financial measures. See "Non-GAAP Financial Measures" for additional information.
(3) Excluding the impact of transaction-related and restructuring-related costs of $81 million, free cash flow for the three months ended September 30, 2026, was $895 million. Excluding the impact of transaction-related costs of $70 million, free cash flow for the three months ended September 30, 2025, was $728 million.
3
Nine Months Ended
September 30,
(Unaudited; in millions, except %s and per share amounts) 20262025Reported Change Operational Change(1) (2)
Total Revenues $11,023.3 $10,596.3 4%2%
Total Net Sales$10,990.3 $10,559.7 4%2%
Developed Markets6,430.4 6,266.6 3%1%
Emerging Markets1,606.8 1,645.4 (2)%(3)%
Greater China2,096.5 1,759.6 19%15%
Net Sales by Product Category
Brands$7,212.3
Aug 6, 2026 · 100% conf.
1D
-1.39%
$16.06
Act: +0.86%
5D
-3.29%
$15.75
20D
-7.42%
$15.08
2 exhibit991-2q26earningsrel.htm
Document
Viatris Reports Second-Quarter 2026 Financial Results
•Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million
•Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025
•Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to Second Quarter 2025
•Advances Key Pipeline Milestones, Including U.S. FDA Approval of Gwyn LoTM
•Announces Sale of Global Rights to Tyrvaya®
•Returns Approximately $550 Million of Capital to Shareholders, Including Through Share Repurchases; Reduces Gross Leverage Ratio to 2.9x
•Raises 2026 Financial Guidance Midpoints for All Metrics [1]
PITTSBURGH – August 6, 2026 – Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced its second-quarter 2026 financial results.
Executive Commentary
“Our second-quarter results reflect another quarter of strong execution and reinforce the momentum we're building across our business,” said Scott A. Smith, CEO, Viatris. “Commercial execution, pipeline progress and the early benefits of our enterprise-wide strategic review continue strengthening our business and improving our financial performance. Our strong first-half results give us the confidence to raise our full-year guidance. We expect a more balanced operating environment in the second half of the year and we remain focused on disciplined execution, investing behind our future growth drivers and creating long-term value for patients and shareholders.”
“We delivered another strong quarter of Total Revenues and Adjusted EBITDA growth over the prior year, reflecting continued strong operational execution,” said Paul Campbell, Interim CFO, Chief Accounting Officer & Corporate Controller, Viatris. “At the same time, we continued to execute on our balanced capital allocation strategy, returning approximately $550 million to shareholders, including approximately $270 million of share repurchases occurring through early August. In addition, we further strengthened our balance sheet and reduced our gross leverage ratio to 2.9x.”
[1] Viatris is not providing forward-looking guidance for U.S. GAAP net earnings (loss) or U.S. GAAP diluted EPS (loss) or a quantitative reconciliation of its 2026 Adjusted EBITDA or Adjusted EPS guidance. U.S. GAAP net cash provided by operating activities for 2026 is estimated to be between $1.9 billion and $2.1 billion, with a midpoint of approximately $2.0 billion. 2026 financial guidance ranges as provided on August 6, 2026, exclude the impact of any transaction-related and restructuring-related costs (as defined below) and acquired IPR&D for unsigned deals as they cannot be reasonably forecasted. Please see “2026 Financial Guidance” and “Non-GAAP Financial Measures” for additional information.
Second-Quarter Results
Three Months Ended
June 30,
(Unaudited; in millions, except %s and per share amounts) 20262025 Reported Change
Operational Change(1) (2)
Total Revenues $3,756.8 $3,582.1 5%4%
Total Net Sales$3,745.9 $3,569.0 5%4%
Developed Markets2,193.7 2,119.3 4%2%
Emerging Markets542.3 555.1 (2)%(2)%
Greater China713.8 588.9 21%16%
Net Sales by Product Category
Brands$2,418.4 $2,284.5 6%4%
Generics 1,327.5 1,284.5 3%3%
U.S. GAAP Gross Profit$1,456.5 $1,332.9 9%
U.S. GAAP Gross Margin38.8 %37.2 %
Adjusted Gross Profit (2) $2,158.9 $2,028.4 6%
Adjusted Gross Margin (2) 57.5 %56.6 %
U.S. GAAP Net Loss$(118.8)$(4.6)NM
U.S. GAAP Loss Per Share$(0.10)$— NM
Adjusted Net Earnings (2) $808.5 $726.0 11%
Adjusted EPS (2) $0.69 $0.62 11%9%
$729.0 $577.8 26%
Adjusted EBITDA (2) $1,188.3 $1,078.8 10%8%
U.S. GAAP Net Cash Provided by Operating Activities $381.8 $219.7 74%
Capital Expenditures 52.8 52.9 —%
Free Cash Flow (2)(3) $329.0 $166.8 97%
(1) See “Certain Key Terms and Presentation Matters” in this release for more information.
(2) Non-GAAP financial measures. See "Non-GAAP Financial Measures" for additional information.
(3) Excluding the impact of transaction-related and restructuring-related costs of $120 million, free cash flow for the three months ended June 30, 2026, was $449 million. Excluding the impact of transaction-related costs of $74 million, free cash flow for the three months ended June 30, 2025, was $241 million.
2
Six Months Ended
June 30,
(Unaudited; in millions, except %s and per share amounts) 20262025Reported Change Operational Change(1) (2)
Total Revenues $7,273.8 $6,836.4 6%3%
Total Net Sales$7,255.6 $6,812.2 7%3%
Developed Markets4,214.5 4,011.0 5%1%
Emerging Markets1,077.7 1,075.0 —%(1)%
Greater China1,393.9 1,144.4 22%17%
Net Sales by Product Category
Brands$4,750.9 $4,401.4 8%4%
Generics 2,504.7 2,410.8 4%2%
U.S. GAAP Gross Profit$2,613.7 $2,494.1 5%
U.S. GAAP Gross Margin35.9 %36.5 %
Adjusted Gross Profit (2) $4,129.2 $3,848.0 7%
May 7, 2026 · 100% conf.
1D
+3.00%
$17.63
Act: -0.03%
5D
+6.88%
$18.30
Act: +0.82%
20D
+3.16%
$17.66
Act: -7.24%
2 exhibit991-1q26earningsrel.htm
Document
Viatris Reports First-Quarter 2026 Financial Results
•Delivers Total Revenues of $3.5 Billion, Representing 8% Reported Growth Compared to First Quarter 2025, and U.S. GAAP Net Earnings of $176 Million
•Total Revenues Were Up 3% Operationally Compared to First Quarter 2025
•Adjusted EBITDA was $1.0 Billion Up 10% Operationally Compared to First Quarter 2025, Demonstrating Solid Operating Leverage
•Progresses Key Launches and Pipeline Milestones Across Multiple Products, Including the Launch of Effexor® for Generalized Anxiety Disorder in Japan
•Continues to Expect More Than $2.5 Billion of Cash Available for Deployment in 2026
•Reaffirms 2026 Financial Guidance [1]
PITTSBURGH – May 7, 2026 – Viatris Inc. (Nasdaq: VTRS) today announced its first-quarter 2026 financial results.
Executive Commentary
“We delivered a strong first quarter, reflecting disciplined execution across our global businesses,” said Scott A. Smith, CEO, Viatris. “Our performance reinforces the growth trajectory we outlined at our Investor Event in March. We saw continued momentum in key markets like Greater China and North America, progressed on launches and advanced our pipeline with multiple near-term catalysts. We expect to generate significant cash in 2026, providing flexibility to execute against our balanced capital allocation framework. Based on our strong start, we believe we are well positioned to deliver on our full-year guidance, and we remain focused on building a more durable, higher-quality growth profile for Viatris.”
[1] Viatris is not providing forward-looking guidance for U.S. GAAP net earnings (loss) or U.S. GAAP diluted EPS (loss) or a quantitative reconciliation of its 2026 Adjusted EBITDA or Adjusted EPS guidance. U.S. GAAP net cash provided by operating activities for 2026 is estimated to be between $1.7 billion and $2.0 billion, with a midpoint of approximately $1.85 billion. 2026 financial guidance ranges as provided on February 26, 2026, and reaffirmed on May 7, 2026, exclude the impact of any transaction-related and restructuring-related costs (as defined below) and acquired IPR&D for unsigned deals as they cannot be reasonably forecasted. Please see “2026 Financial Guidance” and “Non-GAAP Financial Measures” for additional information.
First-Quarter Results
Three Months Ended
March 31,
(Unaudited; in millions, except %s and per share amounts) 20262025Reported Change Operational Change(1) (2)
Total Revenues $3,517.0 $3,254.3 8%3%
Total Net Sales$3,509.7 $3,243.2 8%3%
Developed Markets2,020.8 1,891.7 7%1%
Emerging Markets535.4 519.9 3%—%
Greater China680.1 555.5 22%18%
Net Sales by Product Category
Brands$2,332.5 $2,116.9 10%4%
Generics 1,177.2 1,126.3 5%1%
U.S. GAAP Gross Profit$1,157.2 $1,161.2 —%
U.S. GAAP Gross Margin32.9 %35.7 %
Adjusted Gross Profit (2) $1,970.3 $1,819.6 8%
Adjusted Gross Margin (2) 56.0 %55.9 %
U.S. GAAP Net Earnings (Loss) (3)
U.S. GAAP Earnings (Loss) Per Share (3)
Adjusted Net Earnings (2) $694.1 $600.3 16%
Adjusted EPS (2) $0.59 $0.50 18%14%
Adjusted EBITDA (2) $1,049.5 $923.5 14%10%
U.S. GAAP Net Cash Provided by Operating Activities $388.3 $535.5 (27)%
Capital Expenditures 39.9 42.6 (6)%
Free Cash Flow (2)(4) $348.4 $492.9 (29)%
(1) See “Certain Key Terms and Presentation Matters” in this release for more information.
(2) Non-GAAP financial measures. See “Non-GAAP Financial Measures” for additional information.
(3) For the three months ended March 31, 2025, includes the previously disclosed goodwill impairment charge of $2.9 billion as a result of the interim goodwill impairment test performed as of March 31, 2025.
(4) Excluding the impact of transaction-related and restructuring-related costs of $111 million, free cash flow for the three months ended March 31, 2026, was $459 million. Excluding the impact of transaction-related costs and taxes primarily related to the divestitures of $43 million, free cash flow for the three months ended March 31, 2025, was $535 million.
Financial Highlights for the First Quarter of 2026
•Total revenues were $3.5 billion, up 8% on a reported basis and up 3% on an operational basis compared to first-quarter 2025 results, primarily driven by strong growth in Greater China.
•Brands net sales reflect accelerated growth in Greater China and continued strength in Emerging Markets.
•Generics net sales reflect contributions from new product launches, in addition to growth of certain products in North America, partially offset by supply constraints in our ARV business within Emerging Markets.
2
•The Company generated approximately $71 million in new product revenues in the quarter and continues to expect to deliver approximately $450 million to $550 million in new product revenues in 2026.
•U.S. GAAP net earnings were $176 million compare
See how VTRS stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "VTRS Viatris Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.